Haemonetics (NYSE: HAE) + announced today that it completed its previously announced acquisition of cardiology-focused medical device company OpSens.
Boston-based Haemonetics first announced plans to buy OpSens for more than $250 million in October. Upon completion of the deal, the company acquired all outstanding shares at a fully diluted equity value of about $255 million. As a result, OpSens common shares ceased trading in the public market and will be delisted from the Toronto Stock Exchange.
OpSens offers optical technology for use in interventional cardiology. Core products include the SavvyWire, a sensor-guided, 3-in-1 guidewire for transcatheter aortic valve replacement (TAVR) procedures. SavvyWire acts as a pacing and pressure monitoring wire, advancing procedure workflow and enabling shorter hospital stays.
The company’s OptoWire pressure guidewire aims to improve clinical outcomes by measuring F…